Genetic counseling and predictive testing for hereditary neuromuscular diseases-Reference-Cited by-同舟云学术

Genetic counseling and predictive testing for hereditary neuromuscular diseases

Published:2021 Issue:9 Volume:61 Page:588-593
ISSN:0009-918X
Container-title:Rinsho Shinkeigaku
language:en
Short-container-title:Rinsho Shinkeigaku

Author:

Nakamura Katsuya¹,Sekijima Yoshiki²

Affiliation:

1. Center for Medical Genetics, Shinshu University Hospital

2. Department of Medicine (Neurology and Rheumatology), Shinshu University School of Medicine

Publisher

Societas Neurologica Japonica

Subject

Neurology (clinical)

Link

https://www.jstage.jst.go.jp/article/clinicalneurol/61/9/61_cn-001608/_pdf

Reference30 articles.

1. 1) 保険収載されている遺伝学的検査［Internet］．米子市：厚生労働科学研究費補助金（難治疾患政策研究事業）難病領域における検体検査の精度管理体制の整備に資する研究班［cited 2020 Jan 31］．Available from: http://www.kentaikensa.jp/1391/15921.html

2. 2) 関島良樹．難治性ニューロパチーの新規治療展望　遺伝性ATTRアミロイドーシスの病態に基づいた疾患修飾療法の開発．神経治療学 2018;35:278-282.

3. 3) Waddington CM, Benson MD. A review of tafamidis for the treatment of transthyretin-related amyloidosis. Neurol Ther 2015;4:61-79.

4. 4) Adams D, Gonzalez-Duarte A, O’Riordan WD, et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. N Engl J Med 2018;379:11-21.

5. 5) Finkel RS, Mercuri E, Darras BT, et al. Nusinersen versus Sham Control in infantile-onset spinal muscular atrophy. N Engl J Med 2017;377:1723-1732.

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Genetic counselling for at-risk family members with hereditary transthyretin amyloidosis: data from a single-centre study;Amyloid;2024-05-25

2. Clinical utility of urinary mulberry bodies/cells testing in the diagnosis of Fabry disease;Molecular Genetics and Metabolism Reports;2023-09